TREX1 Cuts Down on Cancer Immunogenicity

Takahiro Yamazaki; Lorenzo Galluzzi

doi:10.1016/j.tcb.2017.06.001

TREX1 Cuts Down on Cancer Immunogenicity

Trends Cell Biol. 2017 Aug;27(8):543-545. doi: 10.1016/j.tcb.2017.06.001. Epub 2017 Jun 15.

Authors

Takahiro Yamazaki¹, Lorenzo Galluzzi²

Affiliations

¹ Department of Radiation Oncology, Weill Cornell Medical College, 10065 New York, NY, USA.
² Department of Radiation Oncology, Weill Cornell Medical College, 10065 New York, NY, USA; Sandra and Edward Meyer Cancer Center, 10065 New York, NY, USA; Université Paris Descartes/Paris V, 75006 Paris, France. Electronic address: [email protected].

PMID: 28625463
DOI: 10.1016/j.tcb.2017.06.001

Abstract

Demaria and colleagues have recently identified three prime repair exonuclease 1 (TREX1) as a key determinant for the limited immunogenicity of cancer cells responding to single high-dose radiation. TREX1 stands out as a promising target for the development of novel strategies to boost anticancer immune responses driven by radiation therapy (RT).

Keywords: STING; abscopal effect; cGAS; checkpoint blockers; immunogenic cell death; type I interferon.

Publication types

News
Research Support, Non-U.S. Gov't

MeSH terms

Animals
Exodeoxyribonucleases / metabolism*
Humans
Mice
Neoplasms / enzymology
Neoplasms / immunology
Neoplasms / radiotherapy*
Phosphoproteins / metabolism*
Radiotherapy Dosage

Substances

Phosphoproteins
Exodeoxyribonucleases
three prime repair exonuclease 1